Medtronic invests in Anteris (ASX: AVR) to fund DurAVR trial and TAVR platform expansion

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has secured a USD 90 million strategic investment from Medtronic plc (NASDAQ: MDT), the world’s largest medical technology company. The deal was completed in parallel with an underwritten public offering of Anteris’ common stock, bringing the total capital raised to USD 320 million. This combined funding round will power Anteris Technologies’ global pivotal PARADIGM clinical trial and advance its regulatory and commercial roadmap for the DurAVR Transcatheter Heart Valve, a balloon-expandable, biomimetic solution engineered for patients with severe aortic stenosis.

The investment positions Anteris Technologies to scale its presence in the structural heart space, strengthen its balance sheet, and drive clinical execution without reliance on near-term licensing, debt, or distribution partnerships. For Medtronic plc, the equity stake offers early exposure to a differentiated valve platform with the potential to complement its existing cardiovascular portfolio. Both companies noted the strategic alignment in their focus on durability, hemodynamic performance, and long-term patient outcomes in the transcatheter aortic valve replacement market.

Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris Technologies, characterized the transaction as a critical milestone that provides not only capital resources but also external validation from both capital markets and a strategic leader in cardiovascular devices. John Seaberg, Chairman of the Anteris Board, emphasized that Medtronic plc’s entry into the shareholder base reflects a shared commitment to disciplined valve innovation and a long-horizon clinical science strategy.

From Medtronic plc’s perspective, the investment reflects confidence in Anteris Technologies’ differentiated design approach. According to Jorie Soskin, Vice President and General Manager of the Structural Heart business within Medtronic plc’s Cardiovascular Portfolio, the decision to support DurAVR technology is consistent with the company’s mandate to define the future of transcatheter aortic valve therapy through performance-led innovation.

What makes the DurAVR heart valve different from other transcatheter valve platforms?

The DurAVR Transcatheter Heart Valve is engineered using a single molded piece of ADAPT tissue, a patented anti-calcification technology developed by Anteris Technologies. This biomimetic design mimics the natural curvature and motion of a healthy aortic valve and is intended to replicate native aortic blood flow. Unlike conventional valves assembled from multiple tissue components, the DurAVR design eliminates stitching interfaces, which are often sites of early wear or stress concentration.

The ADAPT tissue platform has been FDA-cleared and used clinically in over 55,000 patients worldwide. Its anti-calcification properties represent a key competitive differentiator in a market where valve longevity remains a critical concern for both younger patient populations and healthcare systems managing lifetime procedure costs. The valve’s balloon-expandable architecture is designed for precise deployment, positioning Anteris Technologies squarely in the segment currently dominated by Edwards Lifesciences’ Sapien valve franchise.

Crucially, the combination of balloon-expandable deliverability with a biomimetic leaflet structure allows Anteris Technologies to compete not only on valve function, but also on procedural safety, anatomical conformity, and hemodynamic optimization. These factors are especially important in low- to intermediate-risk patients, a cohort that regulators and cardiology societies are now more frequently approving for transcatheter procedures.

How does the PARADIGM trial fit into Anteris Technologies’ long-term regulatory and commercial roadmap?

The PARADIGM trial is a large-scale, prospective, randomized controlled trial designed to evaluate the safety and efficacy of the DurAVR valve against existing commercially approved balloon-expandable valves. The ‘All Comers Randomized Cohort’ will include approximately 1,000 patients globally, with a 1:1 randomization between DurAVR recipients and those receiving other market-approved valves. The trial’s primary composite endpoint includes all-cause mortality, all strokes, and cardiovascular hospitalizations at one year post-procedure.

Initial patient enrollment and valve implantation began in the fourth quarter of 2025. The trial’s structure reflects an ambitious strategy: to position DurAVR not as a niche alternative, but as a head-to-head challenger to the current standard of care. Unlike many early-stage TAVR trials that pursue narrow inclusion criteria or anatomical subtypes, PARADIGM is structured to meet the data expectations of U.S. Food and Drug Administration premarket approval pathways and European CE mark regulators.

The funding from Medtronic plc and the parallel public offering will support trial expansion across additional geographies, scaling of clinical operations, and ongoing data collection. It also strengthens Anteris Technologies’ ability to maintain protocol integrity and ensure statistical power, two key concerns in large, global RCTs.

What does Medtronic gain from this minority investment without formal commercial rights?

While the investment does not currently include commercialization, manufacturing, or co-development rights, it offers Medtronic plc a low-risk financial and strategic position in an emerging competitor. By taking a minority equity stake, Medtronic plc gains early access to a disruptive technology, the ability to monitor clinical progress in real time, and the optionality to expand the relationship if trial data proves compelling.

This structure is becoming increasingly common in cardiovascular medtech, especially in segments with concentrated incumbents. For Medtronic plc, which historically emphasized self-expanding valves through its CoreValve platform, the DurAVR stake provides a hedge and potential growth channel in the balloon-expandable segment, where Edwards Lifesciences remains dominant.

Moreover, the deal reflects an evolution in strategic posture. Rather than acquiring early and bearing regulatory risk, large-cap medtech companies like Medtronic plc are leveraging equity investments to stay close to innovation while retaining capital flexibility. Should DurAVR show superior outcomes, Medtronic plc could pursue deeper integration, distribution, or acquisition without competing offers having had early exposure.

What are the broader implications for valve market dynamics and competitor strategies?

The TAVR market has matured significantly over the past decade, with growth now increasingly tied to long-term performance, anatomical adaptability, and procedural safety in broader patient populations. As younger patients become eligible and long-term outcomes take precedence over immediate procedural success, valve manufacturers are under pressure to innovate on durability, reintervention rates, and patient-specific biomechanics.

Anteris Technologies enters this environment with a differentiated value proposition and a scientifically credible platform. If the PARADIGM trial succeeds in showing non-inferiority or superiority on clinical endpoints, DurAVR could gain market traction not only in niche anatomies, but as a standard platform for first-line valve replacement.

Edwards Lifesciences, which has faced limited competition in the balloon-expandable space, may need to accelerate its own biomimetic R&D efforts or consider strategic partnerships to shore up its portfolio. Meanwhile, smaller TAVR players could face increased difficulty attracting capital as investors and strategics consolidate around proven platforms.

From a procedural standpoint, success of DurAVR could also prompt new guidance from clinical societies and influence payer reimbursement models, particularly if long-term data demonstrate reduced need for reintervention or improved quality-of-life metrics.

How does this transaction strengthen Anteris Technologies’ capital position and market credibility?

With USD 320 million in total capital raised, Anteris Technologies is now among the best-capitalized private or early-commercial cardiovascular medtech companies. The funding provides ample runway to complete its global trial, expand its regulatory strategy, and build out commercial infrastructure for eventual product launch.

The association with Medtronic plc also lends reputational strength, which could enhance Anteris Technologies’ credibility with regulators, clinical sites, and institutional investors. It may also improve Anteris Technologies’ standing with group purchasing organizations, hospital systems, and global distributors when commercialization efforts commence.

Importantly, the capital structure allows Anteris Technologies to preserve independence in the near term while still pursuing value creation opportunities. With clinical, operational, and manufacturing milestones now aligned with a robust funding envelope, Anteris Technologies is structurally positioned to transition from clinical-stage innovation to commercial-scale disruption, provided it can execute consistently across its next two fiscal years.

What Medtronic’s USD 90 million investment signals for Anteris Technologies, rival valve makers, and the future of TAVR

• Anteris Technologies has secured $320 million in capital, including a $90 million strategic investment from Medtronic, to support its global TAVR ambitions.

• The partnership signals Medtronic’s intent to strengthen its position in the balloon-expandable THV market currently led by Edwards Lifesciences.

• DurAVR’s biomimetic valve and ADAPT anti-calcification tissue aim to differentiate it from legacy TAVR platforms on long-term durability and physiological flow.

• The ongoing PARADIGM trial is structured as a randomized, global, head-to-head study against approved commercial TAVRs, enhancing data credibility.

• Initial implants began in late 2025, with recruitment scaling up in 2026 as Anteris prepares for global regulatory submissions.

• Medtronic’s minority stake provides future optionality without immediate commercial entanglement, while validating Anteris’ innovation and execution.

• Competitors like Edwards Lifesciences may need to respond to this emerging threat with R&D acceleration or tighter physician engagement.

• If trial data is positive, Anteris could pursue broader strategic alignment with Medtronic or alternative commercialization structures.

• The deal reinforces the growing investor focus on biomimetic, next-generation valve designs in the structural heart sector.

• Anteris’ capital position now enables aggressive scaling without short-term dilution or dependency on high-cost commercial debt.